论文部分内容阅读
Background The optimization of both erythrocyte transfusion and iron chelating has resulted in a remarkable improvement in the life expectancy of patients with thalassemia major (TM).However,only curative therapy remains allogeneic hematopoietic stem cell transplantation (HSCT).